[1]
|
Lee, H.H., Gwillim, E., Patel, K.R., et al. (2020) Epidemiology of Alopecia Areata, Ophiasis, Totalis, and Universalis: A Systematic Review and Meta-Analysis. Journal of the American Academy of Dermatology, 82, 675-682. https://doi.org/10.1016/j.jaad.2019.08.032
|
[2]
|
Jang, H., Park, S., Kim, M.S., et al. (2023) Global, Regional and National Burden of Alopecia Areata and Its Associated Diseases, 1990-2019: A Systematic Analysis of the Global Burden of Disease Study 2019. European Journal of Clinical Investigation, 53, e13958. https://doi.org/10.1111/eci.13958
|
[3]
|
Simakou, T., Butcher, J.P., Reid, S., et al. (2019) Alopecia Areata: A Multifactorial Autoimmune Condition. Journal of Autoimmunity, 98, 74-85. https://doi.org/10.1016/j.jaut.2018.12.001
|
[4]
|
Bertolini, M., McElwee, K., Gilhar, A., et al. (2020) Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata. Experimental Dermatology, 29, 703-725. https://doi.org/10.1111/exd.14155
|
[5]
|
Pratt, C.H., King, L.E., Messenger, A.G., et al. (2017) Alopecia Areata. Nature Reviews Disease Primers, 3, Article No. 17011. https://doi.org/10.1038/nrdp.2017.11
|
[6]
|
Paus, R., Nickoloff, B. and Ito, T. (2005) A ‘Hairy’ Privilege. Trends in Immunology, 26, 32-40. https://doi.org/10.1016/j.it.2004.09.014
|
[7]
|
Żeberkiewicz, M., Rudnicka, L. and Malejczyk, J. (2020) Immunology of Alopecia Areata. Central European Journal of Immunology, 45, 325-333. https://doi.org/10.5114/ceji.2020.101264
|
[8]
|
Zhou, C., Li, X., Wang, C., et al. (2021) Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management. Clinical Reviews in Allergy & Immunology, 61, 403-423. https://doi.org/10.1007/s12016-021-08883-0
|
[9]
|
Dobreva, A., Paus, R. and Cogan, N.G. (2018) Analysing the Dynamics of a Model for Alopecia Areata as an Autoimmune Disorder of Hair Follicle Cycling. Mathematical Medicine and Biology : A Journal of the IMA, 35, 387-407. https://doi.org/10.1093/imammb/dqx009
|
[10]
|
Paus, R., Ito, N., Takigawa, M., et al. (2003) The Hair Follicle and Immune Privilege. Journal of Investigative Dermatology Symposium Proceedings, 8, 188-194. https://doi.org/10.1046/j.1087-0024.2003.00807.x
|
[11]
|
Anzai, A., Wang, E.H.C., Lee, E.Y., et al.(2019) Pathomechanisms of Immune-Mediated Alopecia. International Immunology, 31, 439-447. https://doi.org/10.1093/intimm/dxz039
|
[12]
|
Xing, L., Dai, Z., Jabbari, A., et al. (2014) Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition. Nature Medicine, 20, 1043-1049. https://doi.org/10.1038/nm.3645
|
[13]
|
Mcelwee, K.J., Freyschmidt-Paul, P. and VitaItacolonna, M. (2005) Transfer of CD8 Þ Cells Induces Localized Hair Loss Whereas CD4 Þ /CD25À Cells Promote Systemic Alopecia Areata and CD4 Þ /CD25 Þ Cells Blockade Disease Onset in the C3H/HeJ Mouse Model. The Journal of Investigative Dermatology, 124, 947-957. https://doi.org/10.1111/j.0022-202X.2005.23692.x
|
[14]
|
Eagle, R.A., Traherne, J.A., Hair, J.R., et al. (2009) ULBP6/RAET1L Is an Additional Human NKG2D Ligand. European Journal of Immunology, 39, 3207-3216. https://doi.org/10.1002/eji.200939502
|
[15]
|
Petukhova, L., Duvic, M., Hordinsky, M., et al. (2010) Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity. Nature, 466, 113-117. https://doi.org/10.1038/nature09114
|
[16]
|
Hashimoto, K., Yamada, Y., Fujikawa, M., et al. (2021) Altered T Cell Subpopulations and Serum Anti-TYRP2 and Tyrosinase Antibodies in the Acute and Chronic Phase of Alopecia Areata in the C3H/HeJ Mouse Model. Journal of Dermatological Science, 104, 21-29. https://doi.org/10.1016/j.jdermsci.2021.09.001
|
[17]
|
Zhang, X., Zhao, Y., Ye, Y., et al. (2015) Lesional Infiltration of Mast Cells, Langerhans Cells, T Cells and Local Cytokine Profiles in Alopecia Areata. Archives of Dermatological Research, 2015, 307, 319-331. https://doi.org/10.1007/s00403-015-1539-1
|
[18]
|
Passeron, T., King, B., Seneschal, J., et al. (2023) Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions. Frontiers in Immunology, 14, Article 1243556. https://doi.org/10.3389/fimmu.2023.1243556
|
[19]
|
Kasumagić-Halilovic, E., Cavaljuga, S., Ovcina-Kurtovic, N., et al. (2018) Serum Levels of Interleukin-2 in Patients with Alopecia Areata: Relationship with Clinical Type and Duration of the Disease. Skin Appendage Disorders, 4, 286-290. https://doi.org/10.1159/000486462
|
[20]
|
Omar, S.I., Hamza, A.M., Eldabah, N., et al. (2021) IFN-α and TNF-α Serum Levels and Their Association with Disease Severity in Egyptian Children and Adults with Alopecia Areata. International Journal of Dermatology, 60, 1397-1404. https://doi.org/10.1111/ijd.15658
|
[21]
|
Barahmani, N., Lopez, A., Babu, D., et al. (2010) Serum T Helper 1 Cytokine Levels Are Greater in Patients with Alopecia Areata Regardless of Severity or Atopy. Clinical and Experimental Dermatology, 35, 409-416. https://doi.org/10.1111/j.1365-2230.2009.03523.x
|
[22]
|
Waśkiel-Burnat, A., Osińska, M., Salińska, A., et al. (2021) The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications. Cells, 10, Article 3397. https://doi.org/10.3390/cells10123397
|
[23]
|
Sato-Kawamura, M., Aiba, S. and Tagami, H. (2003) Strong Expression of CD40, CD54 and HLA-DR Antigen and Lack of Evidence for Direct Cellular Cytotoxicity Are Unique Immunohistopathological Features in Alopecia Areata. Archives of Dermatological Research, 294, 536-543. https://doi.org/10.1007/s00403-002-0354-7
|
[24]
|
Zaaroura, H., Gilding, A.J. and Sibbald, C. (2023) Biomarkers in Alopecia Areata: A Systematic Review and Meta-Analysis. Autoimmunity Reviews, 22, Article ID: 103339. https://doi.org/10.1016/j.autrev.2023.103339
|
[25]
|
Czarnowicki, T., He, H.Y., Wen, H.C., et al. (2018) Alopecia Areata Is Characterized by Expansion of Circulating Th2/Tc2/Th22, within the Skin-Homing and Systemic T-Cell Populations. Allergy, 73, 713-723. https://doi.org/10.1111/all.13346
|
[26]
|
Mohan, G.C. and Silverberg, J.I. (2015) Association of Vitiligo and Alopecia Areata with Atopic Dermatitis: A Systematic Review and Meta-Analysis. JAMA Dermatology, 151, 522-528. https://doi.org/10.1001/jamadermatol.2014.3324
|
[27]
|
Yan, X., Tayier, M., Cheang, S.T., et al. (2023) Hair Repigmentation and Regrowth in a Dupilumab-Treated Paediatric Patient with Alopecia Areata and Atopic Dermatitis: A Case Report. Therapeutic Advances in Chronic Disease, 14. https://doi.org/10.1177/20406223231191049
|
[28]
|
Guttman-Yassky, E., Renert-Yuval, Y., Bares, J., et al. (2022) Phase 2a Randomized Clinical Trial of Dupilumab (Anti-IL-4Rα) for Alopecia Areata Patients. Allergy, 77, 897-906. https://doi.org/10.1111/all.15071
|
[29]
|
Ito, T., Kageyama, R., Nakazawa, S. and Honda, T. (2020) Understanding the Significance of Cytokines and Chemokines in the Pathogenesis of Alopecia Areata. Experimental Dermatology, 29, 726-732. https://doi.org/10.1111/exd.14129
|
[30]
|
Wu, B., Zhang, S., Guo, Z., et al. (2021) The TGF-β Superfamily Cytokine Activin-A Is Induced during Autoimmune Neuroinflammation and Drives Pathogenic Th17 Cell Differentiation. Immunity, 54, 308-323.E6. https://doi.org/10.1016/j.immuni.2020.12.010
|
[31]
|
Guttman-Yassky, E., Nia, J.K., Hashim, P.W., et al. (2018) Efficacy and Safety of Secukinumab Treatment in Adults with Extensive Alopecia Areata. Archives of Dermatological Research, 310, 607-614. https://doi.org/10.1007/s00403-018-1853-5
|
[32]
|
Słowińska, M., Kardynal, A., Warszawik, O., et al. (2010) Alopecia Areata Developing Paralell to Improvement of Psoriasis during Ustekinumab Therapy. Journal of Dermatological Case Reports, 4, 15-17. https://doi.org/10.3315/jdcr.2010.1041
|
[33]
|
Wing, K., Onishi, Y., Prieto-Martin, P., et al. (2008) CTLA-4 Control over Foxp3 Regulatory T Cell Function. Science, 322, 271-275. https://doi.org/10.1126/science.1160062
|
[34]
|
Speiser, J.J., Mondo, D., Mehta, V., et al. (2019) Regulatory T-Cells in Alopecia Areata. Journal of Cutaneous Pathology, 46, 653-658. https://doi.org/10.1111/cup.13479
|
[35]
|
Zheng, Y. and Rudensky. A.Y. (2007) Foxp3 in Control of the Regulatory T Cell Lineage. Nature Immunology, 8, 457-462. https://doi.org/10.1038/ni1455
|
[36]
|
Loh, S.H., Moon, H.N., Lew, B.L., et al. (2018) Role of T Helper 17 Cells and T Regulatory Cells in Alopecia Areata: Comparison of Lesion and Serum Cytokine between Controls and Patients. Journal of the European Academy of Dermatology and Venereology, 32, 1028-1033. https://doi.org/10.1111/jdv.14775
|
[37]
|
Rossi, A., Cantisani, C., Carlesimo, M., et al. (2012) Serum Concentrations of IL-2, IL-6, IL-12 and TNF-α in Patients with Alopecia Areata. International Journal of Immunopathology and Pharmacology, 25, 781-788. https://doi.org/10.1177/039463201202500327
|
[38]
|
Kubo, R., Muramatsu, S., Sagawa, Y., et al. (2017) Activated Regulatory T Cells Are Increased in Patients with Alopecia Areata for Suppressing Disease Acitivity. Journal of Dermatological Science, 86, E27-E28. https://doi.org/10.1016/j.jdermsci.2017.02.080
|
[39]
|
Jalili, R.B., Kilani, R.T., Li, Y., et al. (2023) The Potential of Regulatory T Cell-Based Therapies for Alopecia Areata. Frontiers in Immunology, 14, Article 1111547. https://doi.org/10.3389/fimmu.2023.1111547
|
[40]
|
Ito, T., Ito, N., Saatoff, M., et al. (2008) Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell Attack. The Journal of Investigative Dermatology, 128, 1196-1206. https://doi.org/10.1038/sj.jid.5701183
|
[41]
|
Shi, F.D. and Van Kaer, L. (2006) Reciprocal Regulation between Natural Killer Cells and Autoreactive T Cells. Nature Reviews Immunology, 6, 751-760. https://doi.org/10.1038/nri1935
|
[42]
|
Abou Rahal., J., Kurban, M., Kibbi, A.G. and Abbas, O. (2016) Plasmacytoid Dendritic Cells in Alopecia Areata: Missing Link? Journal of the European Academy of Dermatology and Venereology, 30, 119-123. https://doi.org/10.1111/jdv.12932
|
[43]
|
Ito, T., Suzuki, T., Sakabe, J.I., et al. (2020) Plasmacytoid Dendritic Cells as a Possible Key Player to Initiate Alopecia Areata in the C3H/HeJ Mouse. Allergology International, 69, 121-131. https://doi.org/10.1016/j.alit.2019.07.009
|
[44]
|
Dias De Oliveira, N.F., Santi, C.G., Maruta, C.W., et al. (2021) Plasmacytoid Dendritic Cells in Dermatology. Anais Brasileiros de Dermatologia, 96, 76-81. https://doi.org/10.1016/j.abd.2020.08.006
|
[45]
|
Tomaszewska, K., Kozłowska, M., Kaszuba, A., et al. (2020) Increased Serum Levels of IFN-γ, IL-1β, and IL-6 in Patients with Alopecia Areata and Nonsegmental Vitiligo. Oxidative Medicine and Cellular Longevity, 2020, Article ID: 5693572. https://doi.org/10.1155/2020/5693572
|
[46]
|
Tabara, K., Kozłowska, M., Jędrowiak, A., et al. (2019) Serum Concentrations of Selected Proinflammatory Cytokines in Children with Alopecia Areata. Postepy Dermatologii i Alergologii, 36, 63-69. https://doi.org/10.5114/ada.2019.82826
|
[47]
|
Ma, X., Chen, S., Jin, W. and Gao, Y. (2017) Th1/Th2 PB Balance and CD200 Expression of Patients with Active Severe Alopecia Areata. Experimental and Therapeutic Medicine, 13, 2883-2887. https://doi.org/10.3892/etm.2017.4312
|
[48]
|
Agamia, N., Apalla, Z., El Achy, S., et al. (2020) Interferon-γ Serum Level and Immunohistochemical Expression of CD8 Cells in Tissue Biopsies in Patients with Alopecia Areata in Correlation with Trichoscopic Findings. Dermatologic Therapy, 33, e13718. https://doi.org/10.1111/dth.13718
|
[49]
|
Monteleone, G., Pallone, F. and Macdonald, T.T. (2009) Interleukin-21 as a New Therapeutic Target for Immune-Me-diated Diseases. Trends in Pharmacological Sciences, 30, 441-447. https://doi.org/10.1016/j.tips.2009.05.006
|
[50]
|
Dai, Z., Xing, L., Cerise, J., et al. (2016) CXCR3 Blockade Inhibits T Cell Migration Into the Skin and Prevents Development of Alopecia Areata. Journal of Immunology, 197, 1089-1099. https://doi.org/10.4049/jimmunol.1501798
|
[51]
|
Gilhar, A., Laufer-Britva, R., Keren, A. and Paus, R. (2019) Frontiers in Alopecia Areata Pathobiology Research. The Journal of Allergy and Clinical Immunology, 144, 1478-1489. https://doi.org/10.1016/j.jaci.2019.08.035
|
[52]
|
Kamil, Z.A., Abdullah, G.A. and Zalzala, H.H. (2023) Interleukin-15 and Tumor Necrosis Factor-α in Iraqi Patients with Alopecia Areata. Dermatology Research and Practice, 2023, Article ID: 5109772. https://doi.org/10.1155/2023/5109772
|
[53]
|
Waldmann, T.A. (2004) Targeting the Interleukin-15/Interleukin-15 Receptor System in Inflammatory Autoimmune Diseases. Arthritis Research & Therapy, 6, Article No. 174. https://doi.org/10.1186/ar1202
|
[54]
|
El Aziz Ragab, M.A., Hassan, E.M., El Niely, D.A.E.M., et al.(2020) Serum Level of Interleukin-15 in Active Alopecia Areata Patients and Its Relation to Age, Sex, and Disease Severity. Postepy Dermatologii i Alergologii, 37, 904-908. https://doi.org/10.5114/ada.2020.102103
|
[55]
|
Waldmann, T.A. (2013) The Biology of IL-15: Implications for Cancer Therapy and the Treatment of Autoimmune Disorders. The Journal of Investigative Dermatology Symposium Proceedings, 16, S28-S30. https://doi.org/10.1038/jidsymp.2013.8
|
[56]
|
O’Shea, J.J., Schwartz, D.M., Villarino, A.V., et al. (2015) The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention. Annual Review of Medicine, 66, 311-328. https://doi.org/10.1146/annurev-med-051113-024537
|
[57]
|
O’Shea, J.J. and Plenge, R. (2012) JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease. Immunity, 36, 542-550. https://doi.org/10.1016/j.immuni.2012.03.014
|
[58]
|
Hogan, S., Wang, S., Ibrahim, O., et al. (2019) Long-Term Treatment with Tofacitinib in Severe Alopecia Areata: An Update. The Journal of Clinical and Aesthetic Dermatology, 12, 12-14.
|
[59]
|
Almutairi, N., Nour, T.M. and Hussain, N.H. (2019) Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study. Dermatology, 235, 130-136. https://doi.org/10.1159/000494613
|
[60]
|
King, B., Ohyama, M., Kwon, O., et al. (2022) Two Phase 3 Trials of Baricitinib for Alopecia Areata. The New England Journal of Medicine, 386, 1687-1699. https://doi.org/10.1056/NEJMoa2110343
|
[61]
|
Muddebihal, A, Khurana, A. and Sardana, K. (2023) JAK Inhibitors in Dermatology: The Road Travelled and Path Ahead, a Narrative Review. Expert Review of Clinical Pharmacology, 16, 279-295. https://doi.org/10.1080/17512433.2023.2193682
|
[62]
|
Sechi, A., Song, J., Dell’Antonia, M., et al. (2023) Adverse Events in Patients Treated with Jak-Inhibitors for Alopecia Areata: A Systematic Review. Journal of the European Academy of Dermatology and Venereology, 37, 1535-1546. https://doi.org/10.1111/jdv.19090
|